Effects of Carvedilol or Amlodipine on target organ Damage in L-Name hypertensive rats: Their relationship with blood pressure variability.
Article
Authorship:
Del Mauro J ; Prince P ; DONATO, PABLO MARTIN ; Fernandez Machulsky N ; Moretton M ; Gonzalez GE ; Bertera F ; Carranza A ; Gorzlczany S ; Chiapetta D ; Berg G ; Morales C ; Gelpi RJ ; Taira C ; Hocht CDate:
2017Publishing House and Editing Place:
ElsevierMagazine:
Journal of the American Society of Hypertension - ISSN 1933-1711Elsevier
ISSN:
1933-1711Summary *
Objectives: To compare the effects of chronic oral treatment with carvedilol oramlodipine on blood pressure and blood pressure variability and target organ damage in N-nitro-l-arginine methyl ester (L-NAME) hypertensive rats.Methods: Wistar rats were treated with L-NAME administered in the drinking water for 8 weeks together with oral administration of carvedilol 30 mg/kg (n=6), amlodipine 10 mg/kg (n=6) or vehicle (n=6). At the end of the treatment, echocardiographic evaluation, blood pressure and short-term variability measurements were performed. Left ventricular and thoracic aortas were removed to assess activity of metalloproteinase 2 and 9 and expression levels of transforming growth factor β, tumor necrosis factor α and interleukin-6. Histological samples were prepared from both tissues.Results: Carvedilol and amlodipine induced a comparable reduction of systolic and mean arterial pressure and its short-term variability in L-NAME rats. The expression of transforming growth factor β, tumor necrosis factor α and interleukin-6 decreased in both organs after carvedilol or amlodipine treatment and the activity of metalloproteinase was reduced in aortic tissue. Treatment with carvedilol or amlodipine completely prevented left ventricular collagen deposition and morphometric alterations in aorta.Conclusion: Oral chronic treatment with carvedilol or amlodipine significantlyattenuates blood pressure variability and reduces target organ damage and biomarkers of tissue fibrosis and inflammation in L-NAME hypertensive rats. Information provided by the agent in SIGEVAKey Words
bloqueantes cálcicosbloqueantes betaPresión arterial